Published: Jun, 2018

A copious number of players operate in the global diabetes drugs market on account of entry barriers being low. This makes the landscape both fragmented and competitive. A recent report on the market published by Transparency Market Research predicts the competition to intensify further in the near term owing to the entry of more players and emphasis on product development by the existing ones. Regional expansion strategies of players via mergers and acquisitions and strategic alliances is another method by which players are growing their shares.

Some of the current key companies operating in the global market for diabetes drugs are Boehringer Ingelheim GmbH, Novo Nordisk A/S, Bayer AG, Novartis AG, Sanofi, and Merck & Co.

As per the report, the market would likely register a CAGR of 3.6% over the course of the forecast period between 2017 and 2025 to attain a value of US$ 58.4 bn by 2025-end from US$ 43.1 bn in 2016.

Among the different type of diabetes, type 2 diabetes is at present is grossing maximum revenue in the global market for diabetes drugs. This is because of the increased occurrence of this particular category owing to the rising problem of obesity in urban pockets, bettering healthcare facilities and outreach, and increasing healthcare spends of people. From a geographical standpoint, North America holds a leading share because of unhealthy eating patterns and sedentary lifestyle of its people in general which has led to an alarming rise in the chronic ailment.

global-diabetes-drugs-market.jpg

Sedentary Lifestyle, Resulting in Rising Diabetes Cases, Boosts Market

The global market of diabetic drugs is on the rise owing to the spike in the number of cases of diabetes – both type 1 and type 2. As per a recent report by WHO, around 422 million people worldwide suffer from diabetes. This number is four times that of the number of people afflicted with the disease in 1980. The report observes that even though the prevalence has increased worldwide, low- and middle-income countries are home to most of the diabetic population. While the causes of diabetes are complex and often difficult to find, obesity and lack of physical activities are known to definitely contribute to a degree.

Diabetes of any kind can result in complications in many parts of the body and also up the risk of premature death. According to findings of WHO, in 2012 it claimed around 1.5 million lives all over the world. However, with regular physical activities and healthy diet, alongside proper medication such fallout can be prevented. Rising awareness about the same has served to boost the demand for diabetic drugs in the recent past.

Research and Development of More Effective Products Bodes Well for Growth

Another major factor contributing to the diabetic drugs market is the emergence of more effective products every now and then, thanks to the constant efforts by manufacturers and research institutions in this direction. A noticeable trend in the market is the substantial sales of diabetic drugs through hospital pharmacies. Other distribution channels resulting in sales are retail pharmacies and online pharmacies.

This review is based on the findings of a TMR report, titled, “Diabetes Drugs Market (Therapy - Glucagon-like Peptide-1 (GLP-1) Agonist, Dipeptidyl-peptidase-4 (DPP-4) Inhibitors, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors, and Insulin; Disease Type - Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Impaired Glucose Tolerance and Impaired Fasting Glycaemia; By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017–2025.”

The report segments the Global Diabetes Drugs Market into the following:

Global Diabetes Drugs Market, by Therapy Type

  • Glucagon-like peptide-1 (GLP-1) agonist
  • Dipeptidyl-peptidase-4 (DPP-4) inhibitors
  • Sodium glucose co-transporter 2 (SGLT2) inhibitors
  • Insulin
  • Others

Global Diabetes Drugs Market, by Disease Type

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Impaired Glucose Tolerance and Impaired Fasting Glycaemia
  • By Distribution Channel
  • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Global Diabetes Drugs Market, by Region

  • North America
    • Canada
    • U.S.
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia and New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Rest of Middle East & Africa

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com 
Website: https://www.transparencymarketresearch.com 

.